Patents by Inventor Elisabeth Bock
Elisabeth Bock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110300148Abstract: The present invention relates to small peptides derived from a cytokine, interleukin-4 (IL-4), capable of binding to the IL-4 receptors and inhibiting macrophage activation, and thereby preventing the onset of inflammatory response. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein IL-4 plays a prominent role.Type: ApplicationFiled: November 17, 2009Publication date: December 8, 2011Inventors: Elisabeth Bock, Vladimir Berezin
-
Patent number: 8071549Abstract: The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.Type: GrantFiled: May 4, 2009Date of Patent: December 6, 2011Inventors: Vladislav V Kiselyov, Galina Skladchikova, Vladimir Berezin, Elisabeth Bock
-
Patent number: 8008259Abstract: The present invention relates to peptide sequences capable of stimulating neuronal cell differentiation, neural cell survival and neuronal plasticity associated with memory and learning. The peptide sequences of the invention are derived from the proteins belonging to neurotrophic factors, such as NGF, NT3, NT4/5 and BDNF. The invention also relates to pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of a disease or condition wherein the effects of stimulating neuronal cell differentiation, neuronal cell survival, stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: GrantFiled: November 7, 2006Date of Patent: August 30, 2011Assignee: Copenhagen University, Techtrans UnitInventors: Elisabeth Bock, Vladimir Berezin
-
Patent number: 7951906Abstract: The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound.Type: GrantFiled: February 12, 2009Date of Patent: May 31, 2011Assignee: Enkam Pharmaceuticals A/SInventors: Elisabeth Bock, Vladimir Berezin, Morten Albrechtsen
-
Publication number: 20110098225Abstract: The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role.Type: ApplicationFiled: November 28, 2008Publication date: April 28, 2011Inventors: Vladimir Berezin, Elisabeth Bock, Søren Ebdrup, Boris Klementiev
-
Patent number: 7897723Abstract: The invention relates to new peptide compounds capable of modulating cell proliferation, differentiation, survival and/or motility. The peptide compounds of the invention comprise short peptide fragments of the ErbB receptor and are capable of binding to ErbB and modulating activity of the receptor. The invention also relates to antibodies capable of binding to an epitope comprising a peptide sequence of the invention, pharmaceutical compositions comprising the peptide sequences and/or antibodies and uses thereof for treatment of conditions wherein modulating activity of ErbB is needed.Type: GrantFiled: April 3, 2007Date of Patent: March 1, 2011Assignee: Københavns UniversitetInventors: Elisabeth Bock, Vladimir Berezin, Gro Klitgaard Povlsen
-
Patent number: 7847058Abstract: The present invention relates to a method of modulating differentiation, adhesion and/or survival of the neural cell adhesion molecule (NCAM) presenting cells by providing compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM. The invention provides candidate compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM by using methods for screening and testing described in the application. The invention further relates to pharmaceutical compositions comprising compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM and to use of the pharmaceutical compositions and compounds for the modulation of differentiation, adhesion and/or survival of NCAM presenting cells.Type: GrantFiled: September 29, 2004Date of Patent: December 7, 2010Inventors: Elisabeth Bock, Vladimir Berezin, Vladyslav Soroka, Christina Kasper, Jette Sandholm Jensen Kastrup
-
Publication number: 20100166759Abstract: The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: ApplicationFiled: February 12, 2007Publication date: July 1, 2010Inventors: Vladimir Berezin, Elisabeth Bock, Milena Penkowa
-
Publication number: 20100040623Abstract: The present invention relates to peptide fragments derived from proteins of the S-100 family promoting neural cell survival, differentiation and proliferation. The invention further relates to pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: ApplicationFiled: December 20, 2006Publication date: February 18, 2010Inventors: Elisabeth Bock, Vladimir Berezin, Darya Kiryushko
-
Publication number: 20090305951Abstract: The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.Type: ApplicationFiled: May 4, 2009Publication date: December 10, 2009Inventors: Vladislav V. Kiselyov, Galina Skladchikova, Vladimir Berezin, Elisabeth Bock
-
Publication number: 20090221506Abstract: The present invention relates to peptide fragments derived from the proteins belonging to the TGFbeta superfamily, pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of a disease or condition wherein the effects of stimulating neuronal cell differentiation, neuronal cell survival, stimulating neural plasticity associated with learning and memory and/or inhibiting inflammatory response are beneficial for treatment.Type: ApplicationFiled: August 15, 2006Publication date: September 3, 2009Applicant: Copenhagen UniversityInventors: Elisabeth Bock, Vladimir Berezin
-
Publication number: 20090202554Abstract: The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound.Type: ApplicationFiled: February 12, 2009Publication date: August 13, 2009Applicant: ENKAM PHARMACEUTICALS A/SInventors: VLADIMIR BEREZIN, ELISABETH BOCK, MORTEN ALBRECHTSEN
-
Publication number: 20090197801Abstract: The present invention relates to peptide compounds that are capable of stimulating neuronal differentiation, neurite outgrowth and survival of neural cells, and enhancing synaptic plasticity, learning and memory, methods of treating diseases and conditions of nervous system by administration of compositions comprising said compounds. The compounds and compositions of the invention include peptide sequences that are derived from the sequence of human erythropoietin or proteins that are homologous of human erythropoietin.Type: ApplicationFiled: May 8, 2006Publication date: August 6, 2009Inventors: Vladimir Berezin, Elisabeth Bock
-
Publication number: 20090105149Abstract: The present invention relates to new peptide compounds capable of binding to fibroblast growth factor receptor (FGFR), said compounds comprising two individual amino acid sequences, wherein at least one of the two amino acid sequences is capable of binding to FGFR. The invention discloses the amino acid sequences of the compounds and features pharmaceutical compositions comprising thereof. Invention also relates to uses of the compounds and pharmaceutical compositions comprising thereof for the treatment or prevention of different pathological conditions, wherein FGFR plays a role in pathology and/or recovery from the disease. New peptide compounds of the invention are obtainable by the ligand presenting assembly (LPA) method.Type: ApplicationFiled: August 6, 2004Publication date: April 23, 2009Applicant: ENKAM PHARMACEUTICALS A/SInventors: Morten Albrechtsen, Elisabeth Bock, Vladimir Berezin, Arne Valdemar Holm
-
Publication number: 20090092617Abstract: The invention relates to new peptide compounds capable of modulating cell proliferation, differentiation, survival and/or motility. The peptide compounds of the invention comprise short peptide fragments of the ErbB receptor and are capable of binding to ErbB and modulating activity of the receptor. The invention also relates to antibodies capable of binding to an epitope comprising a peptide sequence of the invention, pharmaceutical compositions comprising the peptide sequences and/or antibodies and uses thereof for treatment of conditions wherein modulating activity of ErbB is needed.Type: ApplicationFiled: April 3, 2007Publication date: April 9, 2009Inventors: Elisabeth Bock, Vladimir Berezin, Gro Klitgaard Povlsen
-
Publication number: 20090074779Abstract: The present invention relates to peptide sequences capable of stimulating neuronal cell differentiation, neural cell survival and neuronal plasticity associated with memory and learning. The peptide sequences of the invention are derived from the proteins belonging to neurotrophic factors, such as NGF, NT3, NT4/5 and BDNF. The invention also relates to pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of a disease or condition wherein the effects of stimulating neuronal cell differentiation, neuronal cell survival, stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: ApplicationFiled: November 7, 2006Publication date: March 19, 2009Applicant: Copenhagen UniversityInventors: Elisabeth Bock, Vladimir Berezin
-
Publication number: 20090074774Abstract: The present invention relates to new peptide compounds capable of direct binding to fibroblast growth factor receptor (FGFR) and activating said receptor. The compounds of the invention comprise peptide fragments of the neural cell adhesion molecule (NCAM) derived from the fibronectin type-III module 1 (F3, 1) of NCAM. Peptide sequences of the invention are capable of stimulating learning and memory and/or neurite outgrowth and/or neural cell survival. Peptide sequences and compounds comprising thereof, according to the invention, may be beneficially used for treatment and/or prevention of different pathological conditions wherein FGFR and/or NCAM play a role in pathology and/or recovery from disease. Accordingly, pharmaceutical compositions comprising the peptide sequences and compounds of the invention are also in the scope of protection.Type: ApplicationFiled: June 17, 2005Publication date: March 19, 2009Inventors: Elisabeth Bock, Vladimir Berezin
-
Publication number: 20080249004Abstract: The present invention relates to a method of modulating differentiation, adhesion and/or survival of the neural cell adhesion molecule (NCAM) presenting cells by providing compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM. The invention provides candidate compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM by using methods for screening and testing described in the application. The invention further relates to pharmaceutical compositions comprising compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM and to use of the pharmaceutical compositions and compounds for the modulation of differentiation, adhesion and/or survival of NCAM presenting cells.Type: ApplicationFiled: September 29, 2004Publication date: October 9, 2008Applicant: ENKAM Pharmaceuticals A/SInventors: Elisabeth Bock, Vladimir Berezin, Vladyslav Soroka
-
Publication number: 20080226639Abstract: The invention relates to new peptide fragments capable of stimulating neurite outgrowth, stimulating of cell survival, stimulating neural plasticity associated with memory and learning, and modulating cell motility. The biological activity of the peptide fragments is associated with their capability of binding and activating a neurotrophin receptor of the Trk family. The peptide fragments of the invention comprise an amino acid motif which is essential for binding and activating a neurotrophin receptor of the Trk family. The invention also concerns pharmaceutical compositions comprising the compounds and uses thereof for prevention and/or treatment of conditions and/or diseases, wherein neurotrophing, Tkr receptors and/or NCAM play an important role, and wherein stimulating of neurite outgrowth, cell survival, neural plasticity associated with memory and learning, and/or modulating cell motility is beneficial for treatment.Type: ApplicationFiled: June 10, 2005Publication date: September 18, 2008Applicant: Enkan Pharmaceuticals A/SInventors: Elisabeth Bock, Vladimir Berezin
-
Patent number: 7402560Abstract: The invention provides novel compounds which are capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM). Additionally, the invention relates to methods for treatment of normal, degenerated and damaged NCAM presenting cells.Type: GrantFiled: November 19, 2004Date of Patent: July 22, 2008Inventors: Lars Christian Ronn, Arne Holm, Marianne Olsen, Soren Ostergaard, Peter H. Jensen, Flemming M. Poulsen, Vladislav Soroka, Igor Ralets, Vladimir Berezin, Elisabeth Bock